Nafoxadol
| Drug Information | |||
|---|---|---|---|
| Image | 
| ||
| Identifiers
DrugBank
ChEBI
|
Chemical Data
| ||
Nafoxadol is a pharmaceutical compound that has been studied for its potential use as an analgesic, particularly in the management of pain. It belongs to the class of drugs known as piperazine derivatives and has been investigated for its effects on the central nervous system.
Pharmacology[edit | edit source]
Nafoxadol acts primarily as a serotonin receptor modulator. It has been shown to interact with various subtypes of serotonin receptors, which are involved in the modulation of pain perception. The exact mechanism by which nafoxadol exerts its analgesic effects is not fully understood, but it is believed to involve the modulation of neurotransmitter release in the central nervous system.
Clinical Use[edit | edit source]
Nafoxadol has been studied in clinical trials for its potential use in treating different types of pain, including neuropathic pain and chronic pain. However, as of the latest updates, it has not been approved for clinical use in any major market. The results of clinical trials have been mixed, with some studies showing promising results while others have not demonstrated significant efficacy compared to placebo.
Side Effects[edit | edit source]
The side effects of nafoxadol are similar to those of other drugs that modulate serotonin receptors. Common side effects may include nausea, dizziness, and headache. More serious side effects could include serotonin syndrome, especially if used in combination with other serotonergic drugs.
Research and Development[edit | edit source]
Research into nafoxadol is ongoing, with studies focusing on its pharmacokinetics, pharmacodynamics, and potential therapeutic applications. The development of nafoxadol has been hampered by the complexity of its interactions with multiple serotonin receptor subtypes, which complicates the prediction of its effects in different patient populations.
Also see[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
